EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer

Jialu Shao, Lei Huang, Wenwen Lai, Yi Zou, Qihua Zhu

Molecules · 02.06.2023 · 28 (11) · 4521

DOI: 10.3390/molecules28114521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 02.06.2023. Verfasst von Jialu Shao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Ataxia Telangiectasia, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ataxia telangiectasia mutated and Rad3-related (ATR), a vital member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, plays a critical role in the DNA damage response (DDR). Tumor cells with a loss of DDR function or defects in the ataxia telangiectasia mutated (ATM) gene are generally more dependent on ATR for survival, suggesting that ATR is an attractive anticancer drug target based on its synthetic lethality. Herein, we present a potent and highly selective ATR inhibitor, ZH-12 (IC50 = 0.0068 μM). It showed potent antitumor activity as a single agent or in combination with cisplatin in the human colorectal adenocarcinoma LoVo tumor xenograft mouse model. Overall, ZH-12 may be a promising ATR inhibitor based on the principle of synthetic lethality and deserves further in-depth study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxia TelangiectasiaNeoplasmsAntineoplastic AgentsHumansMiceAnimalsAtaxia Telangiectasia Mutated ProteinsCisplatinDNA Damage

Stichwörter der Autor:innen

ATMATRATR inhibitorsDDRcancersynthetic lethality

Substanzen

Ataxia Telangiectasia Mutated ProteinsAntineoplastic AgentsCisplatinATR protein, human

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • Department of Pharmacology and Medicinal Chemistry, Jiangsu Vocational College of Medicine, Yancheng 224005, China.
  • Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.

Zitieren

APA

Shao, J., Huang, L., Lai, W., Zou, Y., & Zhu, Q. (2023). Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer. Molecules, 28(11), 4521. https://doi.org/10.3390/molecules28114521

Vancouver

Shao J, Huang L, Lai W, Zou Y, Zhu Q. Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer. Molecules. 2023;28(11):4521. doi:10.3390/molecules28114521

BibTeX
@article{Shao2023,
  author = {Shao, Jialu and Huang, Lei and Lai, Wenwen and Zou, Yi and Zhu, Qihua},
  title = {Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {11},
  pages = {4521},
  doi = {10.3390/molecules28114521}
}
Kostenlos starten →